Skip to content

Study · Not a test of the peptide alone · 1991

1 result

[The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter].

Iangolenko VV

Terapevticheskii arkhiv1 Jan 1991

PMID1725225 (opens in a new tab)PepBankPUB-01725225
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In patients with diffuse toxic goiter of medium gravity, a regimen of mercazolyl, thymalin and piracetam had a beneficial effect on the parameters under study and the clinical course.

    In plain wordsIn patients with diffuse toxic goiter, treatment with mercazolyl, thymalin and piracetam had a beneficial effect on the studied measures and the clinical course.

    Peptide
    Thymalin
    Outcome
    Direction not reportedStudied parameters and clinical course
    Study

    n: not reported in source

    Outcome group
    Thyroid function · Endocrine and hormones

    Source sentences

    Summary
    The treatment with the use of mercazolyl, thymalin and piracetam was found to produce a beneficial effect on the parameters under study and the clinical course of DTG.
    3 context sentences
    Summary · context
    The content of medium-weight molecular peptides (MMP), lipid peroxidation (LPO) activity,
    Summary · context
    group V included patients given mercazolyl, thymalin and piracetam.
    Summary · context
    A study was made of the blood content of MMP and LPO activity before therapy and after euthyroidism attainment.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.